scta01
mAbexperimentalCOVID-19
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
3
Phase 4
0
Earliest trial started Jul 24, 2020 (NCT04483375)
Timeline
Indications
Mechanism of action
- SARS-CoV-2Immunity, passive
SARS-CoV-2 immunity, passive
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05156645 | Phase 1/Phase 2 (Phase 2) | Jan 15, 2022 | Sinocelltech Ltd. |
| NCT04709328 | Phase 2/Phase 3 (Phase 3) | Mar 28, 2021 | Sinocelltech Ltd. |
| NCT04644185 | Phase 2/Phase 3 (Phase 3) | Mar 27, 2021 | Sinocelltech Ltd. |
| NCT04683328 | Phase 2/Phase 3 (Phase 3) | Feb 25, 2021 | Sinocelltech Ltd. |
| NCT04483375 | Phase 1 | Jul 24, 2020 | Capital Medical University, Sinocelltech Ltd. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sinocelltech Ltd. | For profit | 5 | 5 | 3 | 2020 |
| Capital Medical University | Academic/Hospital | 1 | 0 | 1 | 2020 |
2 organizations
Page 1 / 1